- B2B
- Publicly traded
- Multi-product
- Pharma & life sciences
- Parent company
- International operations
- Has in-house R&D
About argenx
Global immunology company focused on developing novel antibody-based medicines for severe autoimmune diseases through collaborations with leading researchers
Key facts
- Industry
- Biotechnology Research
- Company size
- 1,001–5,000 employees
- Headquarters
- boston, massachusetts, United States
- Founded
- 2008
- Revenue
- $4.2BFY2025, publicly reported
- Website
- argenx.com
- linkedin.com/company/argenx
Who should you contact at argenx?
Connect to Tamtam to see the decision-makers at argenx, with verified emails and phone numbers, and find more companies like it.
See who to contact, freeargenx account plan
argenx is a Dutch-Belgian immunology biotech selling VYVGART, the first approved FcRn blocker: $4.2 billion FY2025 product net sales, 1,863 employees.
argenx at a glance
argenx is a B2B company in the Biotechnology Research industry, headquartered in boston, massachusetts, United States.
argenx was founded in 2008.
argenx has 1,001–5,000 employees.
argenx's revenue is $4.2B (FY2025, publicly reported).
Frequently asked questions about argenx
What is argenx's revenue?
argenx's revenue is $4.2B (FY2025, publicly reported).
How many employees does argenx have?
argenx has 1,001–5,000 employees.
Where is argenx headquartered?
argenx is headquartered in boston, massachusetts, United States.
Selling to companies like argenx?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies